Change of Fructose to Fat in South Asians

March 7, 2024 updated by: The Rogosin Institute

Fructose-induced Hepatic De Novo Lipogenesis in South Asians

The purpose of this study is to determine whether hepatic de novo lipogenesis (DNL) in response to the ingestion of a mixture of glucose and fructose is greater in South Asians compared to controls (Caucasians).

Study Overview

Detailed Description

South Asians, who originate from the Indian subcontinent and make up one-fifth of the world's population, are among the highest number who suffer from heart disease and diabetes. The results of many research studies suggest that genes play a role in developing heart disease and diabetes that is made worse by the diet in the United States. Fructose is a sugar widely used in the American diet, and when consumed, it is taken up by the liver and changed into fats through a process called de novo lipogenesis (DNL). The current study will compare this change into fats in the liver between South Asians and Caucasians. The participants will be screened on the initial visit, and on the second visit, the DNL response will be measured in the blood over four hours after drinking one sweetened beverage, containing half glucose, half fructose, similar to a soft drink. We expect that DNL in response to fructose intake is higher in South Asians when compared to Caucasians and may partially explain why South Asians have earlier heart disease and diabetes.

Study Type

Interventional

Enrollment (Actual)

39

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • New York, New York, United States, 10065
        • The Rogosin Institute
      • New York, New York, United States, 10065
        • Weill Cornell Medical College Clinical and Translational Science Center (CTSC)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Males and females, 18-35 years of age.
  • South Asian or Caucasian descent through self-identification (South Asians are to have both biological parents with ancestry from India, Pakistan, Sri Lanka, Nepal and Bangladesh and no known non-South Asian ancestry in parents; Caucasians are to have both biological parents who self-identify as Caucasian and no known non-Caucasian ancestry in parents).
  • Body mass index (BMI) 18.0-24.9 kg/m2 with no history of obesity.
  • Fasting glucose <100 mg/dL, 2h glucose oral glucose tolerance test (OGTT) < 140 mg/dL.
  • triglycerides (TG) <200 mg/dL, HDL cholesterol (HDL-C) >30 mg/dL, LDL cholesterol (LDL-C) <160 mg/dL.
  • Willing and able to stop fish oil, fiber supplement, other non-prescribed vitamins/supplements for 1 week prior to visit #2 until completion of study.
  • Willing to not drink alcohol for 24-hours before visit #2.
  • Willing and able to provide informed consent.

Exclusion Criteria:

  • History of diabetes or other endocrine disorder, hepatitis or other liver disorder, HIV, or autoimmune disease.
  • Medication(s) known to affect lipids, including hormonal contraceptives.
  • Recent acute illness
  • Gastrointestinal disease resulting in significant gastrointestinal dysfunction or malabsorption.
  • Cigarette smoking
  • History of ethanol abuse (current intake >2 drinks/day) or illicit drugs.
  • History of severe psychiatric illness
  • If female, pregnant or breastfeeding
  • Participation in an investigational drug study within one month of screening.
  • Unusual diet or extreme level of physical activity
  • Have any other condition, which in the opinion of the investigator, should prohibit the participation in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: South Asians
Participants in this group have only South Asian heritage. The intervention is Fructose + Glucose Beverage.
Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.
Active Comparator: Caucasians
Participants in this group have only Caucasian heritage. The intervention is Fructose + Glucose Beverage.
Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fold Change in Plasma Very Low Density Lipoprotein (VLDL) Triglyceride Palmitate
Time Frame: 4 hours
Fold change in plasma very low density lipoprotein (VLDL) triglyceride palmitate between South Asians and Caucasians from baseline to 4 hours after an oral challenge of fructose:glucose, 1:1.
4 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fold Changes in VLDL Triglycerides in South Asians and Caucasians
Time Frame: 4 hours
1) A comparison of the fold changes in very low density lipoprotein triglycerides (VLDL TG)in the 2 study groups between 0 and 4 hours.
4 hours
Peak Glucose Levels in 2 Study Groups
Time Frame: 1 hour
A comparison of peak levels of glucose at one hour. Glucose is expected to increase after ingestion of glucose/fructose.
1 hour
Peak Insulin Levels in 2 Study Groups
Time Frame: 1 hour
A comparison of the mean peak insulin level at one hour in each group. Insulin is expected to increase after ingestion of glucose/fructose.
1 hour
Peak Gastric Inhibitory Protein (GIP) Levels in the 2 Study Groups
Time Frame: 2 hours
A comparison of the mean peak gastric inhibitory protein (GIP) at 2 hours in each group. GIP is expected to increase after ingestion of glucose/fructose.
2 hours
Correlations Between Fold Change in VLDL TG Palmitate and Other Biomarkers of Carbohydrate and Fat Metabolism
Time Frame: 4 hours
Correlations between fold change in VLDL TG palmitate at 4 hours with other biomarkers of carbohydrate and fat metabolism in each study group.
4 hours
Fold Changes in Triglycerides in 2 Study Groups
Time Frame: 4 hours
1) A comparison of the fold changes in total triglycerides (TG) in the 2 study groups between 0 and 4 hours.
4 hours
Peak Lactate Levels in 2 Study Groups
Time Frame: 1 hour
A comparison of peak levels of lactate (at one hour). Lactate is expected to increase after ingestion of glucose/fructose.
1 hour
Nadir Non-esterified Fatty Acids (NEFA) Levels in 2 Study Groups
Time Frame: 2 hours
A comparison of the nadir level of non-esterified fatty acids (NEFA at 2 hours). NEFA are expected to decrease.
2 hours
Peak Glucose in 2 Study Groups
Time Frame: 1 hour
A comparison of peak levels of glucose at 1 hour. Glucose is expected to increase after ingestion of glucose/fructose.
1 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lisa Hudgins, MD, The Rogosin Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 2, 2012

Primary Completion (Actual)

October 10, 2013

Study Completion (Actual)

October 10, 2013

Study Registration Dates

First Submitted

March 22, 2012

First Submitted That Met QC Criteria

March 23, 2012

First Posted (Estimated)

March 26, 2012

Study Record Updates

Last Update Posted (Actual)

March 12, 2024

Last Update Submitted That Met QC Criteria

March 7, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Disease

Clinical Trials on Fructose + Glucose Beverage

Subscribe